112 -11 (85) 2025 - Namozova Kh.J. - FEATURES OF THE DEVELOPMENT OF PSYCHOORGANIC SYMPTOMS IN CHRONIC CEREBRAL ISCHEMIA

FEATURES OF THE DEVELOPMENT OF PSYCHOORGANIC SYMPTOMS IN CHRONIC CEREBRAL ISCHEMIA

Namozova Kh.J. - Bukhara State Medical Institute named after Abu Ali ibn Sina, Republican Center for Mental Health, Bukhara Branch Bukhara

Resume

According to the WHO, chronic cerebral ischemia (CHI) has become a global medical and social problem in terms of its impact on the health and vital activity of the population due to the development of disability in 35% of the working-age population and the formation of primary disability. The purpose of the study is to assess the psychoorganic changes in CMI depending on the stage of the disease, to determine the features of their formation. Materials and methods. 172 patients who underwent neurological and psychological examination were divided into 3 groups according to clinical course: 1st group consisted of 62 (36.1%) patients (comparison group) with arterial hypertension, without a pronounced SMI pattern; The 2nd group consisted of 57 (33.1%) patients with the 2nd stage of chronic cerebral ischemia with mild and moderate cognitive impairment; The 3rd group consisted of 53 (30.8%) patients with vascular dementia developed against the background of SMI (main group). The age of patients in the general group ranged from 44 to 73 years, while in the 1st group the age ranged from 44 to 60 years, in the 2nd group from 46 to 73 years, in the 3rd group from 48 to 72 years. In the analysis of psycho-emotional state, we used the DASS-21 (Depression, Anxiety, Stress Scale-21) and HADS (Hospital Anxiety and Depression Scale) scales; to determine cognitive function, we used the Addenbrooke's cognitive examination III, ACE-III scales. Results and discussion. Although the complaints of patients in the 3rd group were insignificant compared to the 2nd and 1st groups, focal neurological symptoms prevailed. Furthermore, the observed symptoms indicated diffuse brain damage in CMI. According to the DASS-21 scale, we witnessed the presence of moderate and high anxiety, manifested in pronounced, deep emotional tension, as well as mental suffering of the patient. The stress scale showed that moderate psychological stress manifested itself practically identically in all three groups, while severe stress was significantly more common in the 2nd group. According to the HADS scale results, subclinical anxiety was found to be almost the same prevalence in all three groups, while severe anxiety was characteristic of almost half of the patients in the 2nd group. The ACE-III scale helped us understand changes in cognitive state in relation to the stages of CMI, the severity of symptoms in cerebrovascular pathology, understanding the clinical picture, when and under what conditions autoregulatory processes and brain reserve properties can be damaged. Conclusion. Psychoorganic pathology, which determines the clinical picture of encephalopathy in CMI, manifests in various forms, accompanied by depression, anxiety, fear, and contributes to the development of cognitive impairment.

Keywords: chronic cerebral ischemia; psychoorganic manifestations; neurological symptoms; DASS-21 scale; HADS scale; Addenbrook-III scale.

First page

650

Last page

659

For citation:Namozova Kh.J. - FEATURES OF THE DEVELOPMENT OF PSYCHOORGANIC SYMPTOMS IN CHRONIC CEREBRAL ISCHEMIA//New Day in Medicine 11(85)2025 650-659 https://newdayworldmedicine.com/en/new_day_medicine/11-85-2025

List of References

  1. Чуканова Е.И. Современные аспекты эпидемиологии и лечения хронической ишемии мозга на фоне артериальной гипертензии (результаты программы КАЛИПСО).
  2. Moorhouse P, Rockwood K. Vascular cognitive impairment: current concepts and clinical developments. Lancet Neurol, 2008;7:246-55.
  3. Vereschagin N.V., Suslina Z.A., Maximova M.Y. Arterial hypertension and cerebrovascular pathology: modern view of the problem. Kardiologia, 2004;3:4-8.
  4. Ajzenk G.Ju., Bartol K. Jeksperiment. Experiment. The most brutal research in psychology. Per. s angl. Moskva: Algoritm Publ.; 2021. (in Russian).
  5. Arvanitakis Z, Shah RC, Bennett DA. Diagnosis and Management of Dementia: Review. JAMA. 2019;322(16):1589-99. DOI:10.1001/jama.2019; 4782.
  6. Belskaya K., Lytaev S. Algorithm for Assessing Auditory Images Perception and Verbal Information. Advances in Intelligent Computing. 2021;1201:30-6.
  7. Bel'skaja K.A., Lytaev S.A. Nejropsihologicheskij analiz kognitivnogo deficita pri shizofrenii. [Neuropsychological analysis of cognitive deficits in schizophrenia]. Fiziologija cheloveka. 2022;48(1):46-56. (in Russian).
  8. Clark B.J., Simmons C.M., Berkowitz L.E., Wilber A.A. The retrosplenial-parietal network and reference frame coordination for spatial navigation. Behav Neurosci. 2018;132(5):416-429. DOI: 10.1037/bne0000260.
  9. Clinical guidelines. Senile asthenia. ICD-10: R-54. Age group: 60 and over. Moscow; 2018. 106 p. (In Russ.).
  10. Cuadrado-Godia E., Dwivedi P., Sharma S. Cerebral Small Vessel Disease: A Review Focusing on Pathophysiology, Biomarkers, and Machine Learning Strategies. J Stroke. 2018;20(3):302-20. doi: 10.5853/jos.2017.02922
  11. Dobrushina O. R., Medvedev V. E. Efficiency and safety of combined therapy of asthenic state with the use of piracetam and B vitamins in the general medical network. Consilium Medicum. 2016;9(18):159-163.
  12. Dobrushina O. R., Medvedev V. E. Combined therapy of neurasthenia in general medical practice. Consilium Medicum. 2016;18(2):95-99.
  13. Huang S, Wang J, Fan DY, et al. The association of serum uric acid with cognitive impairment and ATN biomarkers. Front Aging Neurosci. 2022;14:943380. DOI:10.3389/fnagi.2022.943380.
  14. Gromova O. A., Torshin I. Yu., Stakhovskaya L. V., Pepelyayev Ye. G., Semenov V. A., Nazarenko A. G. Experience of using Mexidol in neurological practice. Zhurnal nevrologii i psikhiatrii im. S. S. Korsakova. 2018;118(10):97-107. DOI: 10.17116/jnevro201811810197.53.
  15. Kotova O. V., Zuykova N. L., Palin A. V., Frolova V. I., Gushanskaya E. V., Salyntsev I. V., Medvedev V. E. Psychopathological disorders in chronic cerebral ischemia: possibilities of prevention. Lechaschy Vrach. 2021;5(24):22-26. DOI: 10.51793/OS.2021.15.98.005.
  16. Kremneva E.I., Suslin A.S., Krotenkova M.V. REJR. REJR 2020;10(4):186-206. (in Russian).
  17. Киспаева Т. Т., Сулейменова Ш. Б., Шуптар С. А., Аймагамбетова Б. М., Саттыбаева Ж. М. Ранние биохимические маркеры когнитивной дисфункции у больных с первичным церебральным инсультом // Медицина и экология, 2012;4:49-51.
  18. Shmidt E.V. Classification of vascular lesions of brain and spinal cord. Korsakov Zhurnal Nevropatologii I Psikhiatryy, 1985;9:1281-1288.

    file

    download